Analysis

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

Regeneron Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to REGN.

websiteREGN/analysis/REGN

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to REGN.

Stock profile

Ticker

REGN

Asset type

Stock

Market cap

$63.95B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Regeneron Pharmaceuticals, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • REGN primary listing
  • RGO
  • 881535
  • REGN34
  • 0R2M
  • 1REGN
  • REGNN
  • 4REGN

Latest Regeneron Pharmaceuticals, Inc. news

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority...

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needsTARRYTOWN, N.Y., June 04,...

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus ...

Inmazeb® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, i...

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review unde...

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therap...

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to re...

Research sections

Valuation

Review valuation context for Regeneron Pharmaceuticals, Inc..

Future growth

Review future growth context for Regeneron Pharmaceuticals, Inc..

Past performance

Review past performance context for Regeneron Pharmaceuticals, Inc..

Financial health

Review financial health context for Regeneron Pharmaceuticals, Inc..

Dividend

Review dividend context for Regeneron Pharmaceuticals, Inc..

Management

Review management context for Regeneron Pharmaceuticals, Inc..

Ownership

Review ownership context for Regeneron Pharmaceuticals, Inc..

Other information

Review other information context for Regeneron Pharmaceuticals, Inc..

Community

Review community context for Regeneron Pharmaceuticals, Inc..